Latest news with #Luprofact
The Hindu
5 days ago
- Business
- The Hindu
IPO-bound Corona Remedies acquires 7 brands from Bayer's pharma division
IPO-bound Corona Remedies has acquired one cardiology and six women's healthcare brands from the pharmaceutical division of Bayer in India. The acquisition of Noklot brand marks its entry into the anti-platelet monotherapy segment, which is valued at ₹1,507 crore and growing at 8%. The acquired women's healthcare portfolio comprising Fostine, Luprofact, Menodac, Ovidac, Spye and Vageston will enhance its presence in the Gonadotrophin and Progesterone Hormone market, which stood at ₹1,862 crore, Ahmedabad-based Corona Remedies said citing MAT June 2025 numbers. The acquisition is effective July 16, the company said without sharing the financials of the transaction. It said the latest acquisition is the fourth from multinational corporations. Sanofi, GlaxoSmithKline and Abbott India were the companies from which it had acquired brands earlier. Corona Remedies had filed Draft Red Herring Prospectus (DRHP), for an initial public offering, with SEBI in April.
&w=3840&q=100)
Business Standard
5 days ago
- Business
- Business Standard
Corona Remedies acquires 7 pharma brands from Bayer India, plans expansion
Ahmedabad-based Corona Remedies on Thursday announced an expansion of its pharmaceutical portfolio, acquiring seven brands from the pharmaceutical division of Bayer in India, effective from 16 July. This move marks Corona Remedies' fourth acquisition from a multinational corporation. The company did not disclose the value of the deal. The acquisition includes Noklot in the cardiology segment and six women's healthcare brands — Fostine, Luprofact, Menodac, Ovidac, Spye and Vageston. This portfolio expansion marks Corona's entry into the Rs 1,507-crore anti-platelet monotherapy market, which is growing at 8 per cent annually, and deepens its footprint in the Rs 1,862-crore gonadotrophin and progesterone hormone segment, used primarily in infertility treatment and pregnancy management. When contacted for financial details of the deal, the company stated that it was unable to disclose them at this time as it has filed for an initial public offering (IPO). The company plans to integrate the newly acquired brands into its existing operations and leverage its extensive sales and distribution network to ensure wider reach across metro, semi-metro, urban and rural regions. Corona Remedies said the brands are expected to deliver growth under its stewardship. GCV Life served as the advisor for the transaction. Founded in 2004, Corona Remedies is a branded pharmaceutical company focused on therapeutic areas such as women's healthcare, cardio-diabetes, urology and pain management. The company employs over 4,000 people and operates two Department of Scientific and Industrial Research (DSIR)-approved research and development centres.
Economic Times
5 days ago
- Business
- Economic Times
CORONA Remedies acquires 7 brands from Bayer's pharma division in India
CORONA Remedies on Thursday said it has acquired seven brands from the pharmaceutical division of Bayer in India for an undisclosed sum. The acquisition includes brands in the cardiology segment (Noklot) and women's healthcare portfolio (Fostine, Luprofact, Menodac, Ovidac, Spye and Vageston) in the Indian market, the company said in a statement. Through the acquisition, the company said it is entering the anti-platelet monotherapy segment while also increasing presence in the cardiology domain.
Time of India
5 days ago
- Business
- Time of India
CORONA Remedies acquires 7 brands from Bayer's pharma division in India
CORONA Remedies on Thursday said it has acquired seven brands from the pharmaceutical division of Bayer in India for an undisclosed sum. The acquisition includes brands in the cardiology segment (Noklot) and women's healthcare portfolio (Fostine, Luprofact, Menodac, Ovidac, Spye and Vageston) in the Indian market , the company said in a statement. Explore courses from Top Institutes in Select a Course Category Public Policy Artificial Intelligence Product Management Digital Marketing Cybersecurity Technology MBA CXO Healthcare Others Data Science Leadership PGDM Design Thinking healthcare Operations Management Data Analytics Data Science Project Management others Management MCA Finance Degree Skills you'll gain: Economics for Public Policy Making Quantitative Techniques Public & Project Finance Law, Health & Urban Development Policy Duration: 12 Months IIM Kozhikode Professional Certificate Programme in Public Policy Management Starts on Mar 3, 2024 Get Details Skills you'll gain: Duration: 12 Months IIM Calcutta Executive Programme in Public Policy and Management Starts on undefined Get Details Through the acquisition, the company said it is entering the anti-platelet monotherapy segment while also increasing presence in the cardiology domain.
